Milestone Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
CARDAMYST's launch shows strong early adoption by electrophysiologists and positive payer coverage. Efforts focus on expanding to cardiologists and boosting patient awareness. Revenue per script should rise as coverage grows and free drug programs taper. The pipeline includes a phase III AFib trial and global expansion.
-
CARDAMYST's first full commercial quarter saw rapid adoption, with over 1,200 prescriptions and more than 1,000 patients treated in Q2 2026. Commercial coverage expanded to over 50% post-quarter, and a pivotal phase III trial for AFib-RVR was initiated, supporting future growth.
-
CARDAMYST's launch addresses a significant unmet need in PSVT, with rapid adoption among prescribers and positive early feedback. Commercial strategy focuses on expanding payer coverage and piloting patient activation, while a phase III AFib trial and a real-world patient registry are set to drive future growth.
-
First quarter post-launch saw strong initial uptake of CARDEMYST, with 600 prescriptions written by over 400 providers and positive feedback from patients and prescribers. Cash position is robust, supporting operations into 2027, and payer coverage is expanding, highlighted by Express Scripts formulary inclusion.
-
CARDAMYST launched as the first new PSVT treatment in decades, offering rapid, at-home relief and strong clinical data. The company is targeting 10,000 key providers with 60 sales reps, secured initial payer coverage, and is advancing a phase III trial for AFib-RVR, supported by $200M in cash and a clear path to break-even.
-
CARDAMYST, a novel nasal spray for PSVT, launched with strong commercial support and no branded competition, targeting 2 million US patients. Early uptake is promising, with expansion plans for atrial fibrillation and ex-US markets via partnerships.
Fiscal Year 2025
-
FDA approval and U.S. launch of CARDAMYST marked a pivotal year, with strong initial prescription activity and a robust $200 million cash position supporting operations into late 2027. Early payer coverage is limited, but commercial and Medicare access are expected to expand in 2026–2027.
-
FDA approved Cardamyst nasal spray for PSVT, offering the first new self-administered treatment in over 30 years. Clinical data show rapid and durable efficacy with a favorable safety profile. Launch plans include mid-Q1 availability, broad provider targeting, and strong payer support.
-
Etripamil (Cardamyst) targets a large SVT market with FDA approval expected by year-end. Launch plans focus on retail access, affordable pricing, and payer engagement, with a staged rollout and strong physician adoption anticipated.
-
CARDAMYST is nearing FDA resubmission for PSVT after addressing CMC issues, with strong clinical data showing rapid conversion and reduced ED visits. Commercial launch preparations are complete, and expansion into AFib with RVR is planned, pending resources.
-
Etripamil (CARDAMYST) is nearing FDA approval for PSVT, with a commercial launch and Phase III AFib trial planned for 2024. Clinical data show rapid, effective, and safe relief, with a strong payer-aligned strategy and long-term exclusivity supporting growth.
-
CARDAMYST is set for a mid-2025 US launch pending FDA approval, with an initial focus on high-value cardiology prescribers and commercial payers. The product targets a significant unmet need in PSVT, offering at-home management and cost offsets, with a rational pricing strategy and robust support infrastructure.
Fiscal Year 2024
-
Etripamil, a nasal spray for PSVT, addresses significant unmet needs by offering rapid, self-administered relief for patients dissatisfied with current therapies or reluctant to undergo ablation. Physicians estimate 20–50% of PSVT patients could benefit, with wearables expanding early diagnosis.